Allergy Shots in Pregnancy: Trimester-by-Trimester Management Guide

For patients already on stable maintenance SCIT before conception, continuation in the second trimester is generally safe per Cox 2011 PP3, Metzger 1978, and Shaikh 1993. The second trimester is often considered the most stable window for SCIT continuation. Clinical practice is to continue at the current maintenance dose without advancing. For patients with both allergic rhinitis and allergic asthma, the second trimester is particularly important for maintaining SCIT-driven asthma control because the gravid uterus progressively reduces functional residual capacity — uncontrolled maternal asthma is itself a fetal-hypoxia risk per Cox 2011 PP3.

Yes. Your obstetric provider should know you are receiving SCIT injections and which allergen extracts your treatment vial contains. While SCIT continuation at maintenance is generally considered safe, your OB-GYN needs this information for complete prenatal care documentation, for coordination with your allergist regarding epinephrine protocols, and to be prepared for the small possibility of a systemic reaction at any trimester visit. Coordination between the prescribing allergist and the obstetric team is standard good practice per Cox 2011 PP3 guidance on managing SCIT in high-risk patients.

Mild nausea and morning sickness are not contraindications to receiving a maintenance SCIT injection. However, if you are experiencing significant gastrointestinal distress, dehydration, or systemic illness on the day of an injection, your allergist may choose to defer — not because of the pregnancy per se, but because any systemic illness can lower the threshold for systemic reactions to SCIT per Cox 2011 PP3 protocols. Mild morning sickness that resolves before the injection appointment is typically not a deferral indication. Discuss your current symptoms with the nurse or allergist before each injection during pregnancy.

Missed-dose protocols during pregnancy follow the same guidelines as outside pregnancy, adjusted for the conservative approach of not advancing doses. If a maintenance interval is exceeded, the allergist typically steps back to a lower dose rather than resuming at the prior maintenance level — this is always cautious practice, and doubly so during pregnancy where the goal is stable maintenance, not dose escalation. Cox 2011 PP3 general missed-dose guidance (typical practice varies by clinic): if more than 4–6 weeks have elapsed since the last maintenance injection, the allergist should reduce the next dose before resuming. Never restart at the prior full maintenance dose after a prolonged gap during pregnancy without allergist consultation.

No harmful effects on the baby from allergen extract SCIT have been documented in the published literature. Both Metzger 1978 (121 pregnancies) and Shaikh 1993 (109 pregnancies) found no significant differences in prematurity, hypertension/proteinuria, or congenital malformations between women on SCIT versus controls. Shaikh 1993 actually found lower prematurity rates in the continuation group. The allergen extract proteins in SCIT vials are not pharmacological drugs — they are FDA-licensed allergen materials at concentrations calibrated to provoke immune response, not to deliver bioactive agents to the fetus.

For patients already on SCIT for allergic asthma at the time they become pregnant, continuing maintenance SCIT may help maintain the asthma-control benefit that SCIT provides — and maintaining good asthma control is a clinical priority during pregnancy because uncontrolled maternal asthma is itself a fetal risk. The Cochrane review (Abramson MJ et al., Cochrane 2010; DOI 10.1002/14651858.CD001186.pub2) found NNT ≈ 3 to avoid asthma symptom deterioration with SCIT across 88 trials. However, SCIT should never be initiated during pregnancy for this purpose — the benefit of starting SCIT during pregnancy does not outweigh the systemic-reaction risk of the build-up phase.